This template was built with Webflow's free Prospero UI Kit. Learn more
When a doctor tells you that your child's seizures may be connected to something called the SCN2A gene, it can feel like stepping into a foreign language. The diagnosis is rare, the science is complex, and the path forward may feel uncertain. You are not alone in that feeling — and you are not starting from zero.
This guide is written for caregivers. It explains what SCN2A epilepsy is, what current science tells us about why it happens, and why understanding your child's specific type of genetic variant matters more than ever for their care.
Genes are the instructions our bodies use to build and run themselves. The SCN2A gene carries instructions for building a specific protein called Nav1.2 — a tiny gateway, called an ion channel, that sits on the surface of brain cells. Nav1.2 controls how electrical signals travel through the brain.
To understand what SCN2A does, imagine a traffic light at a busy intersection. When it works correctly, it keeps brain signals moving in a safe, orderly way. When there is a change — or mutation — in the SCN2A gene, the Nav1.2 channel may not work as it should. The traffic light malfunctions. Signals that should stop keep going, or signals that should flow get blocked.
To learn more about the SCN2A gene and how it affects the brain, visit the SCN2A Foundation's overview page.
A seizure happens when brain cells fire too fast, too often, or in an uncoordinated way. In SCN2A epilepsy, a mutation in the gene causes the Nav1.2 channel to malfunction — leading to abnormal electrical activity that the brain cannot regulate normally. Depending on the type of mutation, that malfunction can push brain activity in very different directions.
SCN2A-related epilepsy is a rare genetic epilepsy. It is diagnosed through genetic testing, not through a blood test or brain scan alone. Because SCN2A mutations are rare, many families experience a long road to diagnosis — sometimes years. But genetic testing is becoming more common when unexplained seizures appear in infants and young children, which is bringing diagnosis timelines down.
Not all SCN2A mutations are the same. Research has identified three broad categories of how an SCN2A mutation can affect the Nav1.2 channel. Understanding which category your child's variant falls into is one of the most important pieces of information a care team can have — though it is worth noting that not all variants have been functionally characterized, and this work is still ongoing.
A gain-of-function (GOF) variant causes the Nav1.2 channel to become overactive. Think of it as a gate that won't fully close — too much electrical signal floods in, and the brain can't keep up. GOF variants are most commonly associated with neonatal-onset epilepsy, meaning seizures that begin in the first days or weeks of life.
Children with GOF variants often experience frequent, hard-to-control seizures very early in life. There is a well-established relationship between GOF variants and early-onset epilepsy — meaning the type of variant tends to correlate with when and how seizures appear, though outcomes can still vary significantly even among children with similar variants.
A loss-of-function (LOF) variant has the opposite effect. The Nav1.2 channel becomes underactive — the gate is too slow to open, or it opens less often than it should. This leads to reduced signaling rather than excessive signaling.
LOF variants are more commonly associated with autism spectrum disorder, intellectual disability, and later-onset epilepsy — if seizures appear at all. This is an important distinction: not every child with an LOF variant will have epilepsy, and some will have neurodevelopmental differences without any seizure history.
The distinction between GOF and LOF variants may influence treatment decisions, though the evidence guiding those decisions is still evolving. It is important that your child's care team is aware of their specific variant type when evaluating options. Always work with a neurologist experienced in genetic epilepsies.
For years, researchers described SCN2A mutations using a simple two-category framework: gain-of-function or loss-of-function. But a growing body of research is revealing that this binary picture does not capture the full biological reality of every variant.
Some SCN2A variants display characteristics of both GOF and LOF at the same time — or behave differently depending on the stage of brain development. These are increasingly recognized as mixed function variants. This is an emerging area of research, and scientists are actively working to better define what mixed function means at the cellular level and what it may mean for clinical outcomes.
A 2024 study published in Brain (Berg et al.) systematically assessed Nav1.2 channel function in 81 patients with 69 unique SCN2A variants. The study found that gain-of-function and some variants with mixed functional properties were observed among children with neonatal-onset epilepsy, while loss-of-function variants were more prevalent in children with later-onset epilepsy and autism without seizures. The authors note that the relationship between variant function and clinical presentation underscores the importance of understanding these distinctions as precision therapies advance.
A 2025 review in Epilepsia (Scott et al.) highlighted the complexity underlying SCN2A variant classification, noting that some variants display characteristics of both GOF and LOF simultaneously, and that channel kinetics alone do not fully predict seizure prognosis or disease severity. This suggests the traditional binary framework may oversimplify the biology for some individuals.
What does this mean for caregivers? It means that functional classification of your child's specific variant — not just knowing they have an SCN2A mutation — is increasingly recognized as important context for care teams, though how classification should guide treatment decisions is still an area of active research. The field is working to develop the tools to characterize variants more precisely at scale. You can follow the latest SCN2A research underway today on the SCN2A Foundation's research page.
SCN2A-related epilepsy is not one condition — it is a spectrum. Seizures can begin within hours of birth or not appear until months or years later. They can be frequent and severe, or in some cases, resolve on their own. The type and timing of seizures are often connected to the variant function category described above, though outcomes vary considerably even among children with similar variants.
Seizure types seen in SCN2A epilepsy include:
• Neonatal-onset seizures: beginning in the first days of life, often associated with GOF or variants with mixed functional properties
• Epilepsy of infancy with migrating focal seizures (EIMFS): a severe early-onset epilepsy syndrome
• Infantile spasms (West syndrome): clusters of brief, sudden seizures in infancy
• Self-limited familial neonatal-infantile epilepsy (SeLFNIE): a milder form in which seizures often resolve by age two
• Later-onset epilepsy: appearing in older infants or children, sometimes alongside developmental differences
SCN2A affects more than seizure activity. Many children with SCN2A mutations — across all variant types — experience developmental differences that are not directly related to seizure frequency. These may include:
• Developmental delay or intellectual disability
• Autism spectrum disorder
• Movement difficulties, including hypotonia (low muscle tone) or dystonia
• Cortical visual impairment (CVI)
• Speech and communication challenges
• Feeding difficulties
The range of symptoms — and their severity — varies widely from child to child, even among children with the same variant type. This variability is one reason why SCN2A-related disorders are described as a spectrum rather than a single condition.
An SCN2A diagnosis can only be confirmed through genetic testing. A standard EEG or MRI may reveal abnormal brain activity or structural differences, but they cannot identify a specific genetic cause. Genetic testing — typically through a blood sample or saliva — looks directly at the DNA for changes in the SCN2A gene.
Most SCN2A mutations are de novo, meaning they occur spontaneously in the child and are not inherited from either parent. (De novo is a Latin term meaning 'from new.') In a small number of cases, an SCN2A mutation can be inherited — usually from a parent who may have had milder or no symptoms. Genetic counseling can help families understand what a diagnosis means for siblings and future pregnancies.
Once a genetic diagnosis is made, connecting with a neurologist who has experience with SCN2A or rare genetic epilepsies is an important next step. Knowing the specific variant — and ideally its functional classification — helps provide useful context for treatment planning and may open doors to clinical trial eligibility as the field advances.
Joining the SCN2A patient registry is one of the most meaningful things a family can do after diagnosis. Registry participation supports research into the natural history of SCN2A disorders and helps accelerate the path toward better treatments.
There is no one-size-fits-all treatment for SCN2A epilepsy. Because GOF and LOF variants affect the Nav1.2 channel in fundamentally different ways, the medications and approaches that may be considered for one variant type may not be appropriate for another. Variant type may influence treatment decisions, though the evidence guiding these decisions is still evolving and should always be evaluated by an experienced specialist.
This is why genetic testing and functional classification are important context before treatment decisions are made. Your child's neurologist should be aware of the specific variant type when evaluating options. Always consult a specialist experienced in genetic epilepsies — ideally one familiar with the GOF/LOF distinction and the emerging understanding of mixed function variants in SCN2A.
The science of SCN2A is advancing rapidly. Researchers are developing precision medicine approaches that aim to target the specific mechanism behind each variant type — rather than simply trying to suppress seizures. Antisense oligonucleotides (ASOs), gene therapy, and other targeted strategies are all actively being explored for SCN2A-related disorders.
As precision therapies move toward clinical trials, researchers are increasingly focused on understanding variant function — GOF, LOF, or variants with mixed properties — to match participants to the right studies and measure the right outcomes. Knowing as much as possible about your child's specific variant positions your family to take advantage of emerging opportunities as this field moves forward.
An SCN2A diagnosis is rare — but you are joining a community of families, researchers, and clinicians who are working urgently toward better outcomes. The research is advancing. The tools for understanding each variant are becoming more sophisticated. The pipeline of potential therapies is growing.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider joining the patient registry to contribute to the data that drives research forward — and making a donation to the SCN2A Foundation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician, neurologist, or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
4. National Institute of Neurological Disorders and Stroke (NINDS). Epilepsy overview
5. Online Mendelian Inheritance in Man (OMIM). SCN2A gene entry #182390
6. Epilepsy Foundation. Genetic testing in epilepsy
Share
When a doctor tells you that your child's seizures may be connected to something called the SCN2A gene, it can feel like stepping into a foreign language. The diagnosis is rare, the science is complex, and the path forward may feel uncertain. You are not alone in that feeling — and you are not starting from zero.
This guide is written for caregivers. It explains what SCN2A epilepsy is, what current science tells us about why it happens, and why understanding your child's specific type of genetic variant matters more than ever for their care.
Genes are the instructions our bodies use to build and run themselves. The SCN2A gene carries instructions for building a specific protein called Nav1.2 — a tiny gateway, called an ion channel, that sits on the surface of brain cells. Nav1.2 controls how electrical signals travel through the brain.
To understand what SCN2A does, imagine a traffic light at a busy intersection. When it works correctly, it keeps brain signals moving in a safe, orderly way. When there is a change — or mutation — in the SCN2A gene, the Nav1.2 channel may not work as it should. The traffic light malfunctions. Signals that should stop keep going, or signals that should flow get blocked.
To learn more about the SCN2A gene and how it affects the brain, visit the SCN2A Foundation's overview page.
A seizure happens when brain cells fire too fast, too often, or in an uncoordinated way. In SCN2A epilepsy, a mutation in the gene causes the Nav1.2 channel to malfunction — leading to abnormal electrical activity that the brain cannot regulate normally. Depending on the type of mutation, that malfunction can push brain activity in very different directions.
SCN2A-related epilepsy is a rare genetic epilepsy. It is diagnosed through genetic testing, not through a blood test or brain scan alone. Because SCN2A mutations are rare, many families experience a long road to diagnosis — sometimes years. But genetic testing is becoming more common when unexplained seizures appear in infants and young children, which is bringing diagnosis timelines down.
Not all SCN2A mutations are the same. Research has identified three broad categories of how an SCN2A mutation can affect the Nav1.2 channel. Understanding which category your child's variant falls into is one of the most important pieces of information a care team can have — though it is worth noting that not all variants have been functionally characterized, and this work is still ongoing.
A gain-of-function (GOF) variant causes the Nav1.2 channel to become overactive. Think of it as a gate that won't fully close — too much electrical signal floods in, and the brain can't keep up. GOF variants are most commonly associated with neonatal-onset epilepsy, meaning seizures that begin in the first days or weeks of life.
Children with GOF variants often experience frequent, hard-to-control seizures very early in life. There is a well-established relationship between GOF variants and early-onset epilepsy — meaning the type of variant tends to correlate with when and how seizures appear, though outcomes can still vary significantly even among children with similar variants.
A loss-of-function (LOF) variant has the opposite effect. The Nav1.2 channel becomes underactive — the gate is too slow to open, or it opens less often than it should. This leads to reduced signaling rather than excessive signaling.
LOF variants are more commonly associated with autism spectrum disorder, intellectual disability, and later-onset epilepsy — if seizures appear at all. This is an important distinction: not every child with an LOF variant will have epilepsy, and some will have neurodevelopmental differences without any seizure history.
The distinction between GOF and LOF variants may influence treatment decisions, though the evidence guiding those decisions is still evolving. It is important that your child's care team is aware of their specific variant type when evaluating options. Always work with a neurologist experienced in genetic epilepsies.
For years, researchers described SCN2A mutations using a simple two-category framework: gain-of-function or loss-of-function. But a growing body of research is revealing that this binary picture does not capture the full biological reality of every variant.
Some SCN2A variants display characteristics of both GOF and LOF at the same time — or behave differently depending on the stage of brain development. These are increasingly recognized as mixed function variants. This is an emerging area of research, and scientists are actively working to better define what mixed function means at the cellular level and what it may mean for clinical outcomes.
A 2024 study published in Brain (Berg et al.) systematically assessed Nav1.2 channel function in 81 patients with 69 unique SCN2A variants. The study found that gain-of-function and some variants with mixed functional properties were observed among children with neonatal-onset epilepsy, while loss-of-function variants were more prevalent in children with later-onset epilepsy and autism without seizures. The authors note that the relationship between variant function and clinical presentation underscores the importance of understanding these distinctions as precision therapies advance.
A 2025 review in Epilepsia (Scott et al.) highlighted the complexity underlying SCN2A variant classification, noting that some variants display characteristics of both GOF and LOF simultaneously, and that channel kinetics alone do not fully predict seizure prognosis or disease severity. This suggests the traditional binary framework may oversimplify the biology for some individuals.
What does this mean for caregivers? It means that functional classification of your child's specific variant — not just knowing they have an SCN2A mutation — is increasingly recognized as important context for care teams, though how classification should guide treatment decisions is still an area of active research. The field is working to develop the tools to characterize variants more precisely at scale. You can follow the latest SCN2A research underway today on the SCN2A Foundation's research page.
SCN2A-related epilepsy is not one condition — it is a spectrum. Seizures can begin within hours of birth or not appear until months or years later. They can be frequent and severe, or in some cases, resolve on their own. The type and timing of seizures are often connected to the variant function category described above, though outcomes vary considerably even among children with similar variants.
Seizure types seen in SCN2A epilepsy include:
• Neonatal-onset seizures: beginning in the first days of life, often associated with GOF or variants with mixed functional properties
• Epilepsy of infancy with migrating focal seizures (EIMFS): a severe early-onset epilepsy syndrome
• Infantile spasms (West syndrome): clusters of brief, sudden seizures in infancy
• Self-limited familial neonatal-infantile epilepsy (SeLFNIE): a milder form in which seizures often resolve by age two
• Later-onset epilepsy: appearing in older infants or children, sometimes alongside developmental differences
SCN2A affects more than seizure activity. Many children with SCN2A mutations — across all variant types — experience developmental differences that are not directly related to seizure frequency. These may include:
• Developmental delay or intellectual disability
• Autism spectrum disorder
• Movement difficulties, including hypotonia (low muscle tone) or dystonia
• Cortical visual impairment (CVI)
• Speech and communication challenges
• Feeding difficulties
The range of symptoms — and their severity — varies widely from child to child, even among children with the same variant type. This variability is one reason why SCN2A-related disorders are described as a spectrum rather than a single condition.
An SCN2A diagnosis can only be confirmed through genetic testing. A standard EEG or MRI may reveal abnormal brain activity or structural differences, but they cannot identify a specific genetic cause. Genetic testing — typically through a blood sample or saliva — looks directly at the DNA for changes in the SCN2A gene.
Most SCN2A mutations are de novo, meaning they occur spontaneously in the child and are not inherited from either parent. (De novo is a Latin term meaning 'from new.') In a small number of cases, an SCN2A mutation can be inherited — usually from a parent who may have had milder or no symptoms. Genetic counseling can help families understand what a diagnosis means for siblings and future pregnancies.
Once a genetic diagnosis is made, connecting with a neurologist who has experience with SCN2A or rare genetic epilepsies is an important next step. Knowing the specific variant — and ideally its functional classification — helps provide useful context for treatment planning and may open doors to clinical trial eligibility as the field advances.
Joining the SCN2A patient registry is one of the most meaningful things a family can do after diagnosis. Registry participation supports research into the natural history of SCN2A disorders and helps accelerate the path toward better treatments.
There is no one-size-fits-all treatment for SCN2A epilepsy. Because GOF and LOF variants affect the Nav1.2 channel in fundamentally different ways, the medications and approaches that may be considered for one variant type may not be appropriate for another. Variant type may influence treatment decisions, though the evidence guiding these decisions is still evolving and should always be evaluated by an experienced specialist.
This is why genetic testing and functional classification are important context before treatment decisions are made. Your child's neurologist should be aware of the specific variant type when evaluating options. Always consult a specialist experienced in genetic epilepsies — ideally one familiar with the GOF/LOF distinction and the emerging understanding of mixed function variants in SCN2A.
The science of SCN2A is advancing rapidly. Researchers are developing precision medicine approaches that aim to target the specific mechanism behind each variant type — rather than simply trying to suppress seizures. Antisense oligonucleotides (ASOs), gene therapy, and other targeted strategies are all actively being explored for SCN2A-related disorders.
As precision therapies move toward clinical trials, researchers are increasingly focused on understanding variant function — GOF, LOF, or variants with mixed properties — to match participants to the right studies and measure the right outcomes. Knowing as much as possible about your child's specific variant positions your family to take advantage of emerging opportunities as this field moves forward.
An SCN2A diagnosis is rare — but you are joining a community of families, researchers, and clinicians who are working urgently toward better outcomes. The research is advancing. The tools for understanding each variant are becoming more sophisticated. The pipeline of potential therapies is growing.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider joining the patient registry to contribute to the data that drives research forward — and making a donation to the SCN2A Foundation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician, neurologist, or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
4. National Institute of Neurological Disorders and Stroke (NINDS). Epilepsy overview
5. Online Mendelian Inheritance in Man (OMIM). SCN2A gene entry #182390
6. Epilepsy Foundation. Genetic testing in epilepsy
Vlad Magdalin
